Labcorp (LH) announced it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. FDA to aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting. Developed by Roche Diagnostics (RHHBY), Labcorp plans to make the test available nationwide by early 2026.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH: